PA-282 Juvenile toxicity program to support use of Cipargamin (KAE609) in paediatric patients with severe malaria

PA-282 Juvenile toxicity program to support use of Cipargamin (KAE609) in paediatric patients with severe malaria

BackgroundSevere malaria is a life-threatening disease with intravenous artesunate as the only recommended first line therapy. Global annual incidence of severe malaria is ~2 million cases with a case fatality rate >5% (despite antimalarial treatment) in endemic regions. Children under 5 years of...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:BMJ global health 2023-12, Vol.8 (Suppl 10), p.A57-A58
Hauptverfasser: Pfeffer, Sabine, Otsyula, Nekoye, Nicholls, Ian, Kos, Claudine, Kolly, Carine, Gandhi, Preetam
Format: Artikel
Sprache:eng
Schlagworte:
Abstracts of Poster and e-Poster Presentations
Malaria
Pediatrics
Toxicity
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:BackgroundSevere malaria is a life-threatening disease with intravenous artesunate as the only recommended first line therapy. Global annual incidence of severe malaria is ~2 million cases with a case fatality rate >5% (despite antimalarial treatment) in endemic regions. Children under 5 years of age account for ~80% of all malaria deaths. Consequently, early evaluation of efficacy and safety in children
ISSN:2059-7908
DOI:10.1136/bmjgh-2023-EDC.141